Last Updated : March 13, 2024
Details
FilesGeneric Name:
Nab-paclitaxel
Project Status:
Active
Therapeutic Area:
Solid tumours
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Sub Line:
Oncology Single Drug Reviews (Non-Sponsored)
Project Number:
PX0348-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
For patients who developed hypersensitivity reactions (HSRs) to taxanes.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 29-Nov-23 |
|---|---|
| Call for patient input open | 29-Nov-23 |
| Call for patient input closed | 29-Jan-24 |
| Call for patient/clinician input closed | 29-Jan-24 |
| Call for industry input open | 29-Nov-23 |
| Call for industry input closed | 29-Jan-24 |
| Submission received | 24-Oct-23 |
| Review initiated | 25-Oct-23 |
| Expert committee meeting (initial) | 10-May-24 |
| Draft recommendation posted for stakeholder feedback | 28-May-24 |
| End of feedback period | 11-Jun-24 |
Files
Last Updated : March 13, 2024